Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11241103
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11241103 on ClinicalTrials.gov |
What this research studies
If I had non-Hodgkin lymphoma, this project would be developing next-generation radioimmunotherapies that pair fully human anti-CD20 antibodies with more targeted radioactive particles to kill lymphoma cells while sparing healthy tissue. The team will run laboratory and animal experiments to compare different radioisotopes and delivery methods and build on earlier FDA-approved CD20 radioimmunotherapies. They will optimize dosing and radiation types better suited for low-burden or residual disease and address past practical and safety limitations. Promising candidates would then be moved toward early clinical testing in patients.
Who could benefit from this research
Good fit: Ideal candidates would be people with CD20-positive B-cell non-Hodgkin lymphoma, especially those with relapsed disease or low-burden residual disease who are seeking new targeted options.
Not a fit: Patients whose tumors do not express CD20, those with disease types unsuitable for targeted radioimmunotherapy, or those who cannot receive radiation or antibody treatments may not benefit.
Why it matters
Potential benefit: If successful, this could raise cure rates and offer more effective, less toxic, and more accessible treatment options for people with CD20-positive NHL.
How similar studies have performed: Older CD20-directed radioimmunotherapies like Zevalin and Bexxar showed activity but had practical limits, and fully human, precision radioisotope approaches represent a newer, largely untested direction in patients.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WAHL, RICHARD LEO — WASHINGTON UNIVERSITY
- Study coordinator: WAHL, RICHARD LEO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.